Drug notes:
SNC103 Clin0 B-cell malignancies; SNC109 Clin0 Glioblastoma multiforme; 4 add'l product RD
About:
Simnova Biotherapeutics is developing cell therapies to treat cancer. Using cutting-edge technologies and platforms, Simnova is primarily focusing on the development of CAR-T cell therapies for oncology, including hematological malignancy and solid tumors. Simnova has a deep knowledge of tumor immunobiology and is also exploring the development of oncolytic viruses, next generation cytokines and cancer vaccines, some of which are in preclinical studies. Meanwhile, initial CAR-T candidates have entered clinical studies for cancer patients.